One sentence summary: This article is the first to elucidate the underlying mechanisms responsible for reversing azole resistance by a diphenyl ether derivative (diorcinol D).
INTRODUCTION
Candida albicans, an opportunistic pathogen of the human oral, gastrointestinal, vaginal, cutaneous and mucosal surfaces (Beck-Sague and Jarvis 1993) , is one of the most common human fungal pathogen, causing high mortality in nosocomial bloodstream infections (Moran et al., 2010) . A network of C. albicans yeasts, pseudohyphae, hyphae and self-produced extracellular matrix makes up the biofilms (Sudbery 2011) , which adhere to the surface of inert or biological surfaces and bring nosocomial infections. In the intensive care units, a total of 87% of bloodstream infections, including candidemia, were associated with central intravenous lines (Richards et al., 2000) . The biofilms also dramatically increase the resistance of antimicrobial drugs up to 10-1000 times, which result in more nosocomial infections and costs (Mah and O'Toole 2001) .
Azoles, such as fluconazole (FLC), are widely used antifungal agents to cure those life-threatening invasive fungal diseases due to their high efficacy, excellent bioavailability, low toxicity and cost (Loeffler and Stevens 2003) . However, as a result of the overuse even abuse of azoles in clinical, more fungal species have counteracted the action of azoles by developing a number of resistance mechanisms (Müller et al., 2000) . The overexpressions of the ATP-binding-cassette (ABC) transporter genes CDR1 and CDR2, the major facilitator superfamily pumps (MDR1 and FLU1) (Calabrese, Bille and Sanglard 2000; Morschhäuser et al., 2007; Holmes et al., 2008) , the point mutations or alterations of a cytochrome P450 (encoded by CYP51) involved in the 14-demethylation of lanosterol in the ergosterol biosynthetic pathway (Martel et al., 2010) are the major resistance mechanisms in C. albicans. Overexpression of the transporter genes, which increases the activity of efflux pumps, leads to more efflux of antifungal agents. Altered sterol composition affects the fluidity and permeability of cytoplasm membrane. They are all together responsible for the azole resistance. In addition, many other elements, such as the molecular chaperone Hsp90 and calcineurin, are also related to the azole resistance (Cowen and Lindquist 2005; Uppuluri et al., 2008) .
The emergence of drug resistance and the limitation of antifungal drugs complicate the management of fungus infections. In addition, the biofilm-related infection, because of its inherent resistance and the existence of persister, disabled a number of currently antifungal treatments (LaFleur, Kumamoto and Lewis 2006; Ramage et al., 2009) . Therefore, new therapies and therapeutical agents are urgently needed to cope with the predicament. It is also helpful to explore the new mechanisms of resistance.
Combination therapy is now considered as an effective approach to improve the efficacy of antimicrobial therapy in the treatment of invasive infections. The application of drug combination has been recognized as an important area for nearly a quarter of a century since 1979 by Bennett et al. (1979) . Nowadays, more attempts have been made to cope with treatment failures by combining different antifungals in vitro and in vivo (Mukherjee et al., 2005; Chang et al., 2012) . Natural products, benefiting by their diverse bioactivities and structures, are an important source of novel chemicals with pharmaceutical potentials (Cragg, Grothaus and Newman 2009) . Diorcinol D (DD) (Fig. 1) , a diphenyl ether derivative, from lichen endophytic fungus Aspergillus versicolor, displayed fungicidal activity. In this study, we aimed to evaluate the antifungal activity and interaction of DD together with FLC against planktonic cells and mature biofilms of clinical azole-resistant and azolesensitive C. albicans isolates in vitro. In addition, we further explored the mechanisms responsible for the synergistic action of DD and FLC combination.
MATERIALS AND METHODS

Strains
Two wild-type strains (SC5314 and YEM30), ten clinical isolates of C. albicans including five FLC-sensitive isolates (18A, 18B, 18C, 11E, 11F with MIC < 2 μg mL −1 ) and five FLC-resistant isolates (23C, 23L, 24F, 28A, 28I with MIC > 128 μg mL −1 ), and six mutant strains (CAF2-1, DSY448, DSY653, DSY465, DSY659 and DSY1050) were used in this study. The clinical strains were kindly donated by Dr Qi Qingsheng from School of Stomatology in Shandong University. The mutant strains were generous gifts from Dr Sanglard (Lausanne, Switzerland) and their genotypes are listed in Table 1 ( Sanglard et al., 1996) . These isolates were stored in physiological saline supplemented with 20% glycerol at -80 • C. All isolates were subcultured on YPD agar plates (2% tryptone, 1% yeast extract, 2% glucose and 2% agar) for 24 h at 30
• C twice and inoculated in YPD broth (2% tryptone, 1% yeast extract, 2% glucose) for overnight culture at 30
• C, 200 rpm before each experiment.
Antifungal agents
DD was a separated compound from A. versicolor, an endophytic fungus, derived from the lichen Lobaria quercizan in our laboratory and its purity is over 98% as analyzed by high-performance liquid chromatography, which was performed on an Agilent 1260 G1311A quat pump equipped with an Agilent 1260 G1322A degasser, an Agilent 1260 G1329B 1260ALS, an Agilent 1260 G1315D DAD detector and a ZORBAX SB-C 18 column (9.4 mm × 250 mm, 5μm) with a flow of 1.8 mL min -1 in 76% MeOH-H 2 O solvent. The cytotoxicity activities against human cell lines were tested. The 
Minimal inhibition concentrations (MICs)
The MICs of wild-type strain SC5314, ten clinical isolates and six deletion mutant strains were determined by the broth microdilution method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines (M27-A3) (CLSI 2008) .
Interactions between DD and FLC against planktonic C. albicans
The interactions of DD and FLC against planktonic C. albicans cells were assessed by broth microdilution checkerboard assays as previously described (Zhou et al., 2012) . The strains were diluted to a final concentration of 0.5-2. (Sun et al., 2009) . All the experiments were performed in triplicate.
Interactions between DD and FLC against mature biofilms
The wild-type strains SC5314, YEM30 and clinical isolates 18B (FLC-sensitive isolate), 28I (FLC-resistant isolate) were used to determine the nature of interactions between DD and FLC against mature biofilms, which was assessed by broth microdilution checkerboard assays as described previously (Zhou et al., 2012) . 100-μL aliquots of initial concentration of 1 × 10 6 cells mL −1 were seeded into 96-well flat-bottomed microtitration plate wells and cultured at 37
• C for 24 h. The supernatant was then discarded and cells were washed twice with sterile phosphate-buffered saline (PBS; pH 7.2). 100-μL aliquots of fresh RPMI 1640 medium with different concentrations of drugs were added into the wells. The concentrations of FLC used in this assay ranged from 64 to 0.06 μg mL −1 with serially 2-fold dilution, and the concentrations of DD ranged from 32 to 0.5 μg mL −1 . After incubation at 37
• C for 24 h, XTT reduction assays were performed to determine the concentrations decreasing 50% growth compared with the vehicle group, which containing 1% final concentration of DMSO, as described previously (Zhou et al., 2012) .
All the experiments were performed in triplicate.
Drug interaction modeling
In order to assess the nature of the in vitro interactions between DD and FLC against planktonic cells and mature biofilms of C. albicans, fractional inhibitory concentration index (FICI) model and E model were used to characterize the interactions between DD and FLC by analyzing the data obtained from broth microdilution checkerboard assays as previously described (Afeltra et al., 2004; Chatzimoschou et al., 2011) . In briefly, the FICI model is described by the equation: FIC = FIC A + FIC B = MIC AB /MIC A + MIC BA /MIC B , where MIC A and MIC B are the MICs of drug A and B acting alone and MIC AB and MIC BA are the concentrations of the drugs A and B at the iso-effective combinations, respectively. According to the results calculated from each data set, synergy is claimed for an FICI value of ≤ 0.5, while antagonism is claimed for an FICI value of > 4, otherwise, the indifference is concluded.
The E model is based on the BI theory as described previously. According to the equation
where E i is the predicted percentage of growth of the combination of the drugs A and B, and E A and E B are the experimental percentages of growth of each drug acting alone, respectively. Interaction is described by the difference (E) between the predicted and measured percentages of growth with drugs A and B at diverse concentrations ( E = E predicted -E measured ). The E A , E B and E measured are obtained directly from the experimental data. In each of the three independent experiments, for each drug combination, an average E is calculated. When the average E is positive and the 95% confidence interval (CI) among the triplicates experiments do not include 0, statistically significant synergy is claimed; when the average E is negative and the 95% CI do not include 0, statistically significant antagonism is claimed. In any other case, the indifference is concluded.
Time-killing test
In order to further confirm the effect of DD alone or in combination with FLC on cell viability, FLC-resistant isolate 28I was used to determine the time-killing curves. The 28I was adjusted to initial inoculum of 1 × 10 5 cells mL −1 in RPMI 1640 medium buffered with MOPS. The DD and FLC were added in the medium at the final concentration of 4 and 0.5 μg mL −1 , respectively. A drug-free sample served as the growth control. The number of viable cells was determined by colony counting at 12, 24 and 48 h after exposure to antifungal agents. If there was a ≥ 2 log 10 CFU mL −1 of decrease compared to the most active agent or a ≥ 2 log 10 CFU mL −1 of increase compared to the least active agent in CFU mL −1 , synergism or antagonism was claimed. Additive action was defined as a < 2 but > 1 log 10 CFU mL −1 decrease compared to the most active agent. In the other case, indifference action was defined as a < 2 but > 1 log 10 CFU mL −1 increase compared to the least active agent (Mukherjee et al., 2005) . The experiment was performed in triplicate and the results were presented as mean values ± standard deviation.
Visualization of mature biofilms
YEM30 was seeded into 96-well plate at the final concentration of 1 × 10 6 cells mL −1 . After incubation at 37
• C for 24 h, the (Jones and Senft 1985) . After incubated at 37
• C for 1 h, the biofilms were washed twice and transferred to a glass slide covered with a coverslip disk carefully. The samples were observed by CLSM using a 63 × objective.
Rh123 efflux
An azole-sensitive C. albicans isolate 18B and azole-resistant isolate 28I were selected to perform the experiment of Rh123 efflux (Clark et al. 1996) . The cells were diluted to the concentration of 1 × 10 6 cells mL 
Expression of CDR1
Candida albicans CASA1 with green fluorescent protein (GFP) tagged CDR1 was used to reveal the expression of Cdr1 by the fluorescence intensity of CDR1-GFP. Log-phase CASA1 cultures were diluted to an inoculum of 1 × 10 6 cells mL −1 with YPD broth.
DD was added to the cultures with final concentrations of 4, 8 and 12 μg mL −1 . The sample without DD served as the control group. After incubation at 35 • C for 3 h, the cells were collected and subjected to the flow cytometry analysis and CLSM observation, respectively. The experiment was repeated three times in three different days. Statistical significances were determined by Student's t-test and statistical significance was determined by P < 0.05.
Estimation of ergosterol biosynthesis
Total intracellular sterols were extracted by the alcoholic KOH method. Briefly, overnight cultured azole-sensitive C. albicans isolate 18B and azole-resistant isolate 28I were inoculated to 50 mL of YPD broth containing various doses of DD and FLC (1 μg mL −1 for 18B, 16 μg mL −1 for 28I) with a final cell density of 5 × 10 6 cells mL −1 . After the incubation of 35 • C for 3 h, the cells were harvested and extracted as described previously (ArthingtonSkaggs et al., 1999) . The extract was scanned spectrophotometrically between 240 and 300 nm. 
The qPCR analysis of CYP51 expression
In order to quantify the expression of CYP51, qPCR was performed. Azole-sensitive C. albicans isolate 18B and azoleresistant isolate 28I were diluted to a cell concentration of 5 × 10 6 cells mL −1 with YPD broth. Different concentrations of DD (8 μg mL −1 ) or FLC (1 μg mL −1 for 18B, 16 μg mL −1 for 28I) were added to the samples. After the incubation at 35
• C for 3 h, the total RNAs were isolated using the hot phenol method as previously described (Wu et al., 2008) and cDNA was synthesized using the RT kit (Toyobo Co., Osaka, Japan). The qPCR was performed with an Eppendorf Mastercycler Real Time PCR System. The primer sequences, reaction systems and conditions were set as our lab described previously (Sun et al., 2010) . The housekeeping gene 18s was taken as the internal reference gene and the data were calculated using the formula 2 − CT . All samples were taken from triplicate independent experiments.
RESULTS
Susceptibilities and interactions of drugs against C. albicans
We firstly measured the antifungal actions of DD and FLC action alone or in combination using broth microdilution checkerboard assay. Wild-type strains, FLC-resistant isolates and FLCsensitive isolates were used in this test. As Table 2 showed, DD action alone displayed prospecting antifungal activities against either planktonic FLC-resistant isolates or FLC-sensitive ones. Meanwhile, DD also possessed active fungicidal activity (MIC = 32 μg mL −1 ) against mature biofilms of SC5314, YEM30, 18B and 28I. Importantly, the combination treatment caused reduction of MICs of FLC against all isolates no matter with planktonic cells or mature biofilms states. The MICs of FLC against planktonic C. albicans decreased from 2-to 16-fold for FLC-sensitive isolates after simultaneous incubation with DD. While more than 250-fold of ≤ 0.5, antagonism was defined as an FICI value of > 4, and indifference was defined as an FICI value of > 0.5 to 4. For the E model, the average E is positive and the 95% CI does not include 0, synergy is claimed. SYN and ANT were the sums of the percentages of all synergistic and antagonistic interactions. The value of sums less than 100% reveals weak, between 100 and 200% reveals moderate, and more than 200% means strong (Afeltra et al., 2004; Chatzimoschou et al., 2011) . reductions were observed against the planktonic FLC-resistant isolates. Furthermore, DD could also enhance the efficacy of FLC combating the mature biofilms. More than 250-fold reductions of the MICs of FLC were obtained when combined with DD against the mature biofilms of four tested strains (Table 2) . Two independent models including FICI and E were utilized to analyze the results obtained from checkerboard analysis (Table 3) . Based on the FICI values, the combination of DD and FLC against planktonic cells caused synergism for wild-type strain SC5314, three FLC-sensitive isolates (18A, 18B, 18C) and all five FLC-resistant isolates (23C, 23L, 24F, 28A, 28I), indifferent interactions for two FLC-sensitive isolates (11E, 11F). Meanwhile, the combination treatment against mature biofilms resulted in synergistic actions for all four tested strains (SC5314, YEM30, 18B and 28I) ( Table 3) .
According to the E values, simultaneous treatment of planktonic FLC-resistant isolates with FLC and DD resulted in synergistic interactions for all five isolates (23C, 23L, 24F, 28A, 28I). The combinations of DD and FLC displayed synergistic actions for wild-type strain SC5314 and three planktonic FLC-sensitive isolates (18A, 18B, 18C), indifferent interactions for other two FLC-sensitive isolates (11E, 11F) because of their 95% CI including 0. In addition, the E results also showed synergistic actions in the four tested strains against mature biofilms (Table 3) . The results of FICI and E model were matched 100%.
A three-dimensional (3D) plot of FLC-resistant isolate 28I was depicted according to the E values obtained from each combination against planktonic C. albicans using OriginPro 7.5 built-in statistical analysis functionality (OriginLab, Northampton, MA, USA) (Fig. 2a) . Peaks above or below the zero plane indicated synergistic or antagonistic interactions, and the zero plane indicated absence of statistically significant interaction. The 3D plot of 28I showed synergy for almost combination. Meanwhile the contour plot was constructed in order to visualize the interaction of different drug concentrations (Fig. 2b) .
Time-killing test
We then performed time-killing test and depicted the timekilling curves based on the colony counting at specific times. The data showed that DD (4 μg mL −1 ) and FLC (0.5 μg mL −1 ) action alone had little antifungal effect on the viable of cells throughout 48 h, but the combination yielded a 2.9, 4.9 and 3.6 log 10 CFU mL −1 decrease compared with 0.5 μg mL −1 FLC alone at 12, 24
and 48 h (Fig. 3) . According to the standards mentioned in the section 'Materials and methods', a significant synergy was also claimed, which is in line with the results according to the FICI and E model. Interestingly, after the treatment of DD and FLC combination for 48 h, the number of viable cells was increased distinctly comparing with 24 h. However, we collected the cells after treated by the combination for 48 h and determined their MICs of DD and FLC. No resistance was obtained for DD or FLC. So the increase of viable cells number implied that the combination of DD and FLC exerted its antifungal activity within a limit time (48 h). Longer treatment would reduce its activity.
The visualization of mature biofilms
The CLSM images of mature biofilms showed 8 μg mL −1 of DD or 0.5 μg mL −1 of FLC action alone has little effect on the survival of Candida cells, while the combination of DD and FLC or high dose of DD treatment (32 μg mL −1 ) resulted in much more dead cells within mature biofilms revealed by FDA (green, survival cells) and PI (red, dead cells) stainings (Fig. 4) .
The effect of DD on the activity of efflux pumps
To investigate the effect of DD on the cellular efflux pump, we measured the efflux of Rh123, which was glucose-dependent efflux, using FLC-sensitive (18B) and FLC-resistant (28I) isolates. When the cells were suspended in PBS containing 1% glucose to start the ATP-driven drug efflux, the cells treated with 8 μg mL
DD showed much lower rates of efflux (56.2 ± 0.8% for 18B and 15.6 ± 1.4% for 28I) than their corresponding untreated groups (64.2 ± 2.2% for 18B and 25.8 ± 1.1% for 28I). The same tendencies were obtained at 4 and 12 μg mL −1 of DD treatments (Fig. 5a ).
Next, we measured the susceptibilities of efflux pumps mutant strains to DD treatments. Table 1 showed that CDR1 deletion mutant DSY448 (MIC = 6 μg mL −1 ) was more susceptible to DD than CDR2 deletion mutant DSY653 or MDR1 deletion mutant DSY465 (MIC = 16 μg mL −1 ). In addition, the double mutant strain DSY659 with the disruption of CDR1 and CDR2 and triple mutant strain DSY1050 with the disruption of CDR1, CDR2 and MDR1 also displayed more sensitive (MIC = 6 μg mL −1 ) to DD. We finally investigated the expression of Cdr1. Candida albicans CASA1, with CDR1 tagged by GFP, was used in this experiment. The up-or downregulation of Cdr1expression was directly related to the intensity variations of GFP fluorescence intensity. DD-treated CASA1 cells were detected by flow cytometry and observed by CLSM. Fig. 6B showed that the treatment of DD induced a notable decrease of fluorescence intensity compared with control. The GMean value of normal CDR1-GFP was 236.8 ± 14.1, while the fluorescence was decreased to 198.0 ± 14.5, 153.0 ± 6.9 and 28.4 ± 0.8 under 4, 8 and 12 μg mL −1 of DD treatment, respectively. The same tendency was also obtained by confocal microscopic observation (Fig. 5c ). The treatment of DD resulted in a reduction of the fluorescence of CDR1-GFP, indicative of the damage of the efflux pump. Above all, DD could block the activity of efflux pump at least partially by reducing the expression of Cdr1.
The effect of DD on the synthesis of ergosterol
To clarify whether DD regulated the biosynthesis of ergosterol, we measured the content of total intracellular sterols. Fig. 6a and b showed the UV spectrophotometric sterol profiles of FLC-sensitive (18B) and FLC-resistant (28I) isolates after treated with different concentrations of DD and FLC. The data were calculated as described in the section 'Materials and methods', and the results showed DD caused a 6.1 ± 1.6, 24.7 ± 2.2 and 33.2 ± 2.5% reductions in ergosterol content for the FLC-sensitive isolate 18B, at the doses of 4, 8 and 12 μg mL −1 , respectively. 21.4 ± 1.4, 26.8 ± 0.6 and 37.2 ± 2.9% decreases were obtained when FLC-resistant isolate 28I was exposed to 4, 8 and 12 μg mL −1 of DD. FLC as the positive control almost inhibited the ergosterol biosynthesis completely. 1 μg mL −1 of FLC resulted in 97.5% ± 3.0% inhibition for 18B and 16 μg mL −1 of FLC resulted in 98.6% ± 2.4% inhibition for 28I (Fig. 6c) . The results demonstrated the addition of DD could decrease the intracellular sterols of C. albicans, which facilitated the antifungal action of azoles. In addition, qPCR was performed to detect the transcriptional levels of CYP51, the target of FLC and also a critical gene involving in the biosynthesis of ergosterol. The resultant data revealed that DD caused reductions of CYP51 expression by 2.8-and 1.8-fold for 18B and 28I, respectively. While the positive control FLC induced 2.4-and 2.3-fold upregulations for 18B and 28I, respectively, probably due to the feedback regulation (Fig. 6d) .
In conclusion, DD could perturb the biosynthesis of ergosterol through inhibiting the expression of CYP51.
DISCUSSION
The clinically overuse of azoles causes the emergence of azole resistance, which exacerbates the clinical fungal infection cases. Moreover, some clinical isolates exhibit cross-resistance to a variety of different azole drugs (Müller et al., 2000) . Combination therapy is a useful approach to overcome those difficultto-treat infections. Current combination research is evolving to combine clinical antifungal drug with other antifungal agents (Roling et al., 2002) , non-antifungal agents (Zhou et al., 2012) or natural compounds (Sun et al., 2010) . The combination of antifungal drugs has many potential benefits, such as a broader spectrum, reduced toxicity, lower likelihood of emergence of acquired resistance and synergistic or additive interactions (Johnson et al., 2004) .
In this study, we tested the combination of DD and FLC against the planktonic cells and mature biofilms of wild-type strains, clinical FLC-sensitive and -resistant isolates. FICI and E models were utilized to evaluate the combination efficacy. DD alone displayed active antifungal activity towards both azolesensitive and azole-resistant C. albicans isolates. A synergistic action was observed when DD was applied with FLC for most of tested C. albicans isolates, particularly for azole-resistant isolates. In addition, FLC action alone failed to kill mature biofilms of C. albicans for either wild-type or clinical strains, while FLC treatment together with DD synergistically killed the cells within the mature biofilms, which revealed by the evaluation of FICI and E models. Meanwhile, the images of CLSM also showed that DD dramatically enhanced the fungicidal activity of FLC against mature biofilms, indicative of FDA and PI staining.
The overexpression of efflux pumps genes, which results in the increase of azole efflux, is a major mechanism of azole resistance (Morschhäuser 2010) . The more intracellular Rh123 accumulation in the treatment group suggested that DD blocked the activity of efflux pumps. The mediators of azole efflux pumps include the ABC transporters Cdr1p and Cdr2p and the major facilitator superfamily pumps Mdr1p and Flu1p. However, CDR1 mutant strain DSY448 rather than CDR2 mutant strain DSY653 or MDR1 mutant strain DSY465 was hypersusceptible to DD. In addition, CDR1 contributes more than CDR2 to FLC efflux in FLCresistant strains as reported previously (Holmes et al., 2008) . So CDR1 was regarded as the key gene for the DD inhibition. We indeed found that DD could cause the decrease of CDR1-GFP expression via both flow cytometry and CLSM observation. These results supported a conclusion that DD resulted in the more intracellular retention of FLC in C. albicans cells through retarding the efflux pumps.
Another mechanism of azoles resistance is point mutations or alterations of the genes, especially for CYP51 and ERG5, which are involved in ergosterol biosynthesis pathway (Martel et al., 2010) . Because CYP51 precedes ERG5 in sterol biosynthesis, the CYP51, as the target of FLC, appears to be more important. Meanwhile, the C. albicans strains with decreased ergosterol content were known to more sensitive to azoles (Sun et al., 2010) . In this study, the production of ergosterol and the expression of CYP51 were quantified. Our data showed that DD dramatically blocked the ergosterol synthesis and retarded the CYP51 expression. So, altered membrane sterol composition, affecting the membrane permeability and fluidity, acted as another potential mechanism for DD to reverse the drug resistance of FLCresistant isolates.
In this study, the drug doses used in this synergistic test were determined according to the checkerboard data in vitro. The effective doses in different conditions, especially in vivo test, were needed further investigation. We have clarified the underlying mechanisms of the FLC resistance reversing by DD against planktonic cells. Whether this is also applied to mature biofilms needs further investigation.
In summary, we evaluated the interactive effects between DD and FLC against clinical C. albicans isolates using different methods. Strong synergies were obtained for most isolates against planktonic cells and mature biofilms. It was worth mentioning that DD could reverse the drug resistance of clinical FLCresistant isolates. The mechanism investigations indicated that both the inhibition of efflux pump activity and the interference of ergosterol synthesis pathway contributed to the synergistic action. This is the first time to report the activity and mechanism of the natural diphenyl ether derivative against C. albicans alone or in combination with FLC. It provides an alternative clinical application in overcoming fungal infection.
